DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Wednesday. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $4.19 on Wednesday. The stock has a market cap of $86.18 million, a price-to-earnings ratio of -0.93 and a beta of 0.67. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $9.09. The firm’s 50-day simple moving average is $4.06 and its 200 day simple moving average is $3.83.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.